Search Within

Gilles Andre Salles

Formats
  1. Meeting Abstract (181)
  2. Journal Article (74)
  3. Research Letter (18)
  4. Review (17)
  5. Editorial (5)
  6. Correspondence (3)
  7. Conference Paper (2)
  8. Guidelines (2)
  9. Book Section (1)
Groups
  1. Department of Medicine (303)
  2. Hematologic Malignancies, Division of (303)
  3. Center for Hematologic Malignancies (163)
  4. Lymphoma (159)
  5. Survivorship Research (115)
  6. Graduate Medical Education (106)

More Groups

People
  1. Maria Palomba (108)
  2. Andrew Zelenetz (74)
  3. Lorenzo Falchi (64)
  4. Anita Kumar (63)
  5. Gunjan Shah (61)
  6. Miguel-Angel Perales (59)

More People

Years
  1. 2025 (20)
  2. 2024 (67)
  3. 2023 (97)
  4. 2022 (69)
  5. 2021 (44)
  6. 2020 (6)
Publications
  1. Blood (126)
  2. Hematological Oncology (28)
  3. Journal of Clinical Oncology (17)
  4. Blood Advances (16)
  5. Haematologica (14)
  6. British Journal of Haematology (9)

More Publications

Publishers
  1. American Society of Hematology (143)
  2. Wiley Blackwell (30)
  3. Elsevier Inc. (20)
  4. American Society of Clinical Oncology (17)
  5. Ferrata Storti Foundation (14)
  6. Nature Publishing Group (14)

More Publishers

Results (303)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Indolent lymphomas: Introduction to a series highlighting progress and ongoing challenges
    Review

    Smith, S. M.; Salles, G.
    Haematologica (2022)

    Fulltext@MSK | Save
  • Prospects in the management of patients with follicular lymphoma beyond first-line therapy
    Journal Article

    Qualls, D.; Salles, G.
    Haematologica (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schòˆder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: A multicenter observational study
    Meeting Abstract

    Tomas, A. A.; Fein, J. A.; Fried, S.; Fingrut, W.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; Lin, R. J.; Scordo, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interviews of patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) enrolled in 2 lisocabtagene maraleucel (liso-cel) trials on their treatment experience for 3 months after infusion
    Meeting Abstract

    Siddiqi, T.; Jaeger, U.; Moshkovich, O.; Braverman, J.; Liu, F. F.; Lanar, S.; Miera, M.; Shah, S.; Devlen, J.; Salles, G.
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Efficacy comparison of tisagenlecleucel versus standard of care in patients with relapsed or refractory follicular lymphoma
    Meeting Abstract

    Salles, G.; Schuster, S. J.; Dreyling, M. H.; Fischer, L.; Kuruvilla, J.; Patten, P. E. M.; Von Tresckow, B.; Smith, S. M.; Ubieto, A. I. J.; Davis, K. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Tafasitamab plus lenalidomide versus pola-BR, R2, and CAR T: Comparing outcomes from RE-MIND2, an observational, retrospective cohort study in relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Nowakowski, G. S.; Yoon, D. H.; Mondello, P.; Joffe, E.; Fleury, I.; Peters, A.; Greil, R.; Ku, M.; Marks, R.; Kim, K.; more...
    Blood (2021)

    Fulltext@MSK | Save